Scott I Abrams

28PUBLICATIONS
68CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsInnate immunityHaematological tumoursMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|May 20, 2026
Immunological consequences of chemotherapy: implications for cancer immunotherapy.

|Mar 07, 2026
TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.

Christos Fountzilas, Spencer Rosario, Agnieszka K Witkiewicz

|Dec 11, 2024
Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors.

Yuhao Shi, Amber McKenery, Melissa Dolan

|Oct 07, 2024
Consequences of the perivascular niche remodeling for tumoricidal T-cell trafficking into metastasis of ovarian cancer.

Danuta Kozbor, Marta Winkler, Nemi Malhotra

|Mar 20, 2024
Identification of Enhanced Vaccine Mimotopes for the p15E Murine Cancer Antigen.

Shiqi Zhou, Yiting Song, Yuan Luo

|Mar 08, 2024
Aryl hydrocarbon receptor suppresses STING-mediated type I IFN expression in triple-negative breast cancer.

Jeffrey C Martin, Tatiane da Silva Fernandes, Kanita A Chaudhry

Pageof 5

Frequent Collaborators

5 joint publications

Jonathan F Lovell

5 joint publications

Jason B Muhitch

4 joint publications

Mark Long

3 joint publications

Fumito Ito